dc.creator | Allison, Ron R. | |
dc.creator | Bagnato, Vanderlei Salvador | |
dc.creator | Sibata, Claudio H. | |
dc.date.accessioned | 2016-03-11T14:03:41Z | |
dc.date.accessioned | 2018-07-04T16:53:06Z | |
dc.date.available | 2016-03-11T14:03:41Z | |
dc.date.available | 2018-07-04T16:53:06Z | |
dc.date.created | 2016-03-11T14:03:41Z | |
dc.date.issued | 2010 | |
dc.identifier | Future Oncology,London : Future Medicine,v. 6, n. 6, p. 929-940, 2010 | |
dc.identifier | 1479-6694 | |
dc.identifier | http://www.producao.usp.br/handle/BDPI/49941 | |
dc.identifier | 10.2217/FON.10.51 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1641689 | |
dc.description.abstract | Photodynamic therapy (PDT) is a tumor-ablative and function-sparing oncologic
intervention. The relative simplicity of photosensitizer application followed by light
activation resulting in the cytotoxic and vasculartoxic photodynamic reaction
has allowed PDT to reach a worldwide audience. With several commercially
available photosensitizing agents now on the market, numerous well designed
clinical trials have demonstrated the efficacy of PDT on various cutaneous and
deep tissue tumors. However, current photosensitizers and light sources still have
a number of limitations. Future PDT will build on those findings to allow development
and refinement of more optimal therapeutic agents and illumination devices.
This article reviews the current state of the art and limitations of PDT, and highlight
the progress being made towards the future of oncologic PDT. | |
dc.language | eng | |
dc.publisher | Future Medicine | |
dc.publisher | London | |
dc.relation | Future Oncology | |
dc.rights | Copyright Future Medicine | |
dc.rights | restrictedAccess | |
dc.subject | Future | |
dc.subject | Photodynamic therapy | |
dc.subject | Photosensitizer | |
dc.title | Future of oncologic photodynamic therapy | |
dc.type | Artículos de revistas | |